John Collinge (MRC Prion Unit, University College London, London, UK) discusses a first-in-human treatment programme to give PRN100, an anti-prion-protein monoclonal antibody, to patients with Creutzfeldt–Jakob disease; the report is published in the April issue of The Lancet Neurology.

Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.

Giuseppe Citerio (University of Milano-Bicocca, Milan, Italy) discusses the implications of a study from the CENTER-TBI project of the effect of frailty on 6-month outcome after traumatic brain injury, which is published in the February issue of The Lancet Neurology.

Alberto Costa (Case Western Reserve University, Cleveland, OH, USA) discusses his study on the use of memantine in adolescents and young adults with Down syndrome, which is published in the January issue of The Lancet Neurology.

Olivier Rascol (Toulouse University, France) discusses the uses of amantadine in the treatment of patients with movement disorders, which are the focus of his Personal View in the December issue of The Lancet Neurology.

Antonio Uccelli (University of Genoa) discusses his research, published in the November issue of The Lancet Neurology, on the therapeutic use of mesenchymal stem cells for multiple sclerosis.

Priya Palta (Columbia University, New York) explains the importance of blood pressure control in the prevention of cognitive decline. Her Review, published in the October issue of The Lancet Neurology, provides an update of the mounting evidence that links hypertension with dementia risk.

Adam Boxer (University of California, San Francisco) discusses his research, published in the September issue of The Lancet Neurology, on diagnostic performance of tau biomarkers in neurodegenerative diseases.

Irene Cortese (National Institute of Neurological Disorders and Stroke) discusses the difficulties of designing clinical trials in progressive multifocal leukoencephalopathy.

Doug Turnbull (University of Newcastle) discusses mitochondrial diseases in adults, which are reviewed in the July issue of The Lancet Neurology, and explains how important these diseases are for neurologists.